Michael P. Manns
YOU?
Author Swipe
View article: From model to man: Understanding Tregs' dual role in MASLD
From model to man: Understanding Tregs' dual role in MASLD Open
View article: Association Between Sustained Virological Response and Adverse Liver-related Events in Patients With Decompensated Hepatitis C Virus Cirrhosis
Association Between Sustained Virological Response and Adverse Liver-related Events in Patients With Decompensated Hepatitis C Virus Cirrhosis Open
SVR was associated with a reduced risk of LREs in patients with decompensated HCV cirrhosis with a MELD score <15, whereas no clinical benefit was observed in those with higher MELD scores despite an SVR-associated MELD decrease.
View article: Best practices for screening, testing, diagnosing, and treating patients with hepatitis D (delta) virus based on global expert review and recent guidelines
Best practices for screening, testing, diagnosing, and treating patients with hepatitis D (delta) virus based on global expert review and recent guidelines Open
Background Hepatitis D virus (HDV) represents the most severe form of human viral hepatitis, associated with rapid progression to cirrhosis and increased liver-related mortality. Globally, an estimated 9-19 million individuals are anti-HDV…
View article: Extrahepatic Replication and Genomic Signatures of the Hepatitis E Virus in the Kidney
Extrahepatic Replication and Genomic Signatures of the Hepatitis E Virus in the Kidney Open
Introduction The hepatitis E virus (HEV; species Paslahepevirus balayani ) is a common human pathogenic and zoonotic virus that can cause both acute fulminant and chronic hepatitis. Despite its reputation as a hepatotropic virus, HEV infec…
View article: In vivo RNAi screen and validation reveals Ngp, Hba-a1, and S100a8 as novel inhibitory targets on T lymphocytes in liver cancer
In vivo RNAi screen and validation reveals Ngp, Hba-a1, and S100a8 as novel inhibitory targets on T lymphocytes in liver cancer Open
Background Hepatocellular carcinoma (HCC) represents the third deadliest cancer worldwide with limited treatment options. Immune checkpoint inhibitors (ICIs) have revolutionized HCC therapy, but immune suppression within the tumor microenv…
View article: Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity
Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity Open
Overall, we have developed two promising new mouse models that are suitable for preclinical studies of MASLD as they recapitulate most of the key features of MASLD.
View article: Essential roles of B cell subsets in the progression of MASLD and HCC
Essential roles of B cell subsets in the progression of MASLD and HCC Open
Hepatocellular carcinoma (HCC) is the primary liver cancer with a constantly rising mortality rate. Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging important cause of HCC. Current treatment options for HCC a…
View article: Detection of polyreactive immunoglobulin G facilitates diagnosis in children with autoimmune hepatitis
Detection of polyreactive immunoglobulin G facilitates diagnosis in children with autoimmune hepatitis Open
View article: Author Correction: The cellular level of telomere dysfunction determines induction of senescence or apoptosis in vivo
Author Correction: The cellular level of telomere dysfunction determines induction of senescence or apoptosis in vivo Open
View article: Whole-exome sequencing reveals novel cancer genes and actionable targets in biliary tract cancers in primary sclerosing cholangitis
Whole-exome sequencing reveals novel cancer genes and actionable targets in biliary tract cancers in primary sclerosing cholangitis Open
Background: People with primary sclerosing cholangitis (PSC) have a 20% lifetime risk of biliary tract cancer (BTC). Using whole-exome sequencing, we characterized genomic alterations in tissue samples from BTC with underlying PSC. Methods…
View article: Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation
Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation Open
View article: Blockade of neutrophil extracellular trap components ameliorates cholestatic liver disease in Mdr2 (Abcb4) knockout mice
Blockade of neutrophil extracellular trap components ameliorates cholestatic liver disease in Mdr2 (Abcb4) knockout mice Open
Primary sclerosing cholangitis (PSC) is an (auto)immune-mediated cholestatic liver disease with a yet unclear etiology. Increasing evidence points to an involvement of neutrophils in chronic liver inflammation and cirrhosis but also liver …
View article: Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients
Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients Open
View article: Entzündliche Lebererkrankungen
Entzündliche Lebererkrankungen Open
View article: The EASL–Lancet Commission on liver health in Europe: prevention, case-finding, and early diagnosis to reduce liver-related mortality
The EASL–Lancet Commission on liver health in Europe: prevention, case-finding, and early diagnosis to reduce liver-related mortality Open
View article: Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study
Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study Open
View article: Gewichtsverlust bei chronischen Erkrankungen – eine adäquate Behandlung ist essenziell für die Betroffenen!
Gewichtsverlust bei chronischen Erkrankungen – eine adäquate Behandlung ist essenziell für die Betroffenen! Open
View article: Correction: LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries
Correction: LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries Open
View article: Quality‐of‐life scores improve after 96 weeks of <scp>PEG‐IFNa</scp>‐2a treatment of hepatitis D: An analysis of the <scp>HIDIT‐II</scp> trial
Quality‐of‐life scores improve after 96 weeks of <span>PEG‐IFNa</span>‐2a treatment of hepatitis D: An analysis of the <span>HIDIT‐II</span> trial Open
Background & Aims Infection with the hepatitis D virus (HDV) causes the most severe form of viral hepatitis with a high risk to develop clinical complications of liver disease. In addition, hepatitis delta has been shown to be associated w…
View article: Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report
Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report Open
View article: Supplementary Figure 2B from BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma
Supplementary Figure 2B from BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma Open
(B) The phosphorylation of the given proteins in lysates of HepG2 (left), Hep3B (middle) and Huh-7 (right) cells after treatment with 0.2, 1, and 5µM GW5074 or sunitinib at different time points. The values represent MFI of 30-60 beads for…
View article: Data from BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma
Data from BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma Open
Purpose: Small molecule inhibitors of the mitogen-activated protein kinase (MAPK) pathway, such as sorafenib, represent novel treatment options for advanced hepatocellular carcinoma. The aim of our study was to identify downstream t…
View article: Supplementary Table 1 from BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma
Supplementary Table 1 from BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma Open
Two way ANOVA statistics of phosphorylated MEK1 and ERK1/2 after MAPKi treatment. Values of phosphoplex data of mean fluorescence intensities (MFI) from 30-60 beads for each kinase at each time point were calculated against the respective …
View article: Supplemetary Figure S3 from Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer
Supplemetary Figure S3 from Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer Open
Immunohistochemical analysis of E-Cadherin expression
View article: Supplementary Figure S5 from Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer
Supplementary Figure S5 from Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer Open
NK cell cytotoxicity assay
View article: Supplemental Figure 1 from CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations
Supplemental Figure 1 from CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations Open
This figure demonstrates the ability of CD8 T cells induced by DC/CoAT immunizations to migrate to the bronchoalveolar space
View article: Data from BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma
Data from BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma Open
Purpose: Small molecule inhibitors of the mitogen-activated protein kinase (MAPK) pathway, such as sorafenib, represent novel treatment options for advanced hepatocellular carcinoma. The aim of our study was to identify downstream t…
View article: Supplementary Methods and Legend from BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma
Supplementary Methods and Legend from BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma Open
Supplementary Methods and Legend
View article: Supplementary Figure 1 from BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma
Supplementary Figure 1 from BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma Open
Modulation of MEK1 and ERK1/2 phosphorylation by MAPK inhibitors. Phospho-MEK1 and p-ERK1/2 at 0.5, 6, 12, 24, 48, 72 and 96h were detected in lysates of HCC cell lines HepG2 (left), Hep3B (middle) and Huh-7 (right) cells following treatme…
View article: Supplemental Figure 2 from CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations
Supplemental Figure 2 from CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations Open
This figure demonstrates the spectrum of secreted cytokines in CD8 T cells induced by DC/CoAT vaccinations